OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Geoffrey Alan Watson, Jeffrey Doi, Aaron R. Hansen, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 9, pp. 1753-1768
Open Access | Times Cited: 14
Geoffrey Alan Watson, Jeffrey Doi, Aaron R. Hansen, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 9, pp. 1753-1768
Open Access | Times Cited: 14
Showing 14 citing articles:
Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
Youwen Zhu, Kun Liu, Dong Ding, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Youwen Zhu, Kun Liu, Dong Ding, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma
C. Baston, Andreea Paroşanu, Ioana-Miruna Stanciu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1111-1111
Open Access | Times Cited: 5
C. Baston, Andreea Paroşanu, Ioana-Miruna Stanciu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1111-1111
Open Access | Times Cited: 5
Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics
Margherita Passariello, Lorenzo Manna, Rosa Rapuano Lembo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Margherita Passariello, Lorenzo Manna, Rosa Rapuano Lembo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report
Shimpei Eguchi, Hiroji Shinkawa, Yasunori Sato, et al.
Clinical Journal of Gastroenterology (2021) Vol. 14, Iss. 3, pp. 858-865
Closed Access | Times Cited: 7
Shimpei Eguchi, Hiroji Shinkawa, Yasunori Sato, et al.
Clinical Journal of Gastroenterology (2021) Vol. 14, Iss. 3, pp. 858-865
Closed Access | Times Cited: 7
Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy
Yingjie Ma, Junxian Yu, Xiaoting Ma, et al.
Asia-Pacific Journal of Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 180-187
Open Access | Times Cited: 2
Yingjie Ma, Junxian Yu, Xiaoting Ma, et al.
Asia-Pacific Journal of Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 180-187
Open Access | Times Cited: 2
Nucleolar protein TAAP1/C22orf46confers pro-survival signaling in non-small cell lung cancer
Marietta Döring, Melanie Brux, Maciej Paszkowski‐Rogacz, et al.
Life Science Alliance (2024) Vol. 7, Iss. 4, pp. e202302257-e202302257
Open Access
Marietta Döring, Melanie Brux, Maciej Paszkowski‐Rogacz, et al.
Life Science Alliance (2024) Vol. 7, Iss. 4, pp. e202302257-e202302257
Open Access
Identification of risk factors for gastrointestinal immune–related adverse events associated with immune check point inhibitors
Ryo Morikawa, Kentaro Nitta, Shuntarô Yasuda, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Ryo Morikawa, Kentaro Nitta, Shuntarô Yasuda, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers
Armin Nejat Dehkordi, Moein Maddahi, Parinaz Vafa, et al.
Clinical & Translational Oncology (2024)
Closed Access
Armin Nejat Dehkordi, Moein Maddahi, Parinaz Vafa, et al.
Clinical & Translational Oncology (2024)
Closed Access
Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1.
A.S. Vickram, Saghya Infant Shofia, A. Saravanan, et al.
PubMed (2024) Vol. 23, pp. 1303-1326
Closed Access
A.S. Vickram, Saghya Infant Shofia, A. Saravanan, et al.
PubMed (2024) Vol. 23, pp. 1303-1326
Closed Access
Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology
Jennifer Martin, Lionel D. Lewis
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 9, pp. 1674-1677
Open Access | Times Cited: 2
Jennifer Martin, Lionel D. Lewis
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 9, pp. 1674-1677
Open Access | Times Cited: 2
Molecular imaging of tumor-specific markers and their expression in other organs
Diwakar Jain
Journal of Nuclear Cardiology (2020) Vol. 28, Iss. 3, pp. 822-824
Open Access | Times Cited: 1
Diwakar Jain
Journal of Nuclear Cardiology (2020) Vol. 28, Iss. 3, pp. 822-824
Open Access | Times Cited: 1
Predictive Biomarkers of Thyroid Dysfunctions Associated with the Treatment of Non-Small Cell Lung Cancer and Cervical Cancer with Immune Checkpoint Inhibitors
Ketevan Lomidze, Nino Kikodze, Marine Gordeladze, et al.
(2023)
Open Access
Ketevan Lomidze, Nino Kikodze, Marine Gordeladze, et al.
(2023)
Open Access
Immuno-oncology therapies: a looming mid-life crisis?
Han‐Soo Kim, Danny Liew, Stephen Goodall
Immuno Oncology Insights (2022) Vol. 03, Iss. 02, pp. 73-79
Open Access
Han‐Soo Kim, Danny Liew, Stephen Goodall
Immuno Oncology Insights (2022) Vol. 03, Iss. 02, pp. 73-79
Open Access
